Evidence map›Paper›PMID 41054681›Full record

ArticleCureus2025

Capecitabine-Induced Ileitis: A Case Report and Review of the Literature.

Hanna Mohammed Sherief, Anita Nagetey, Muhammad Fahad, Qurrat Ul Ain Tahir

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hanna Mohammed SheriefOncology, University Hospital Coventry and Warwickshire, Coventry, GBR.
Anita NageteyInternal Medicine, University Hospital Coventry and Warwickshire, Coventry, GBR.
Muhammad FahadOncology, University Hospital Coventry and Warwickshire, Coventry, GBR.
Qurrat Ul Ain TahirOncology, University Hospital Coventry and Warwickshire, Coventry, GBR.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Capecitabine-induced ileitis is a rare but important complication, and awareness of this entity is crucial for oncologists and gastroenterologists to ensure timely recognition, appropriate management, and to avoid unnecessary interventions. We present the case of a 62-year-old woman with recurrent estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative left breast cancer who developed vomiting and diarrhea following an increased dose of capecitabine. She was managed conservatively with intravenous fluids, antibiotics, and antiemetics. Imaging suggested findings consistent with ileitis. She was advised to rest her bowel and gradually reintroduce oral intake as tolerated, while receiving symptom relief with antiemetics and loperamide for diarrhea. Her blood parameters were closely monitored, and electrolyte imbalances were corrected as needed. With symptomatic improvement, she was discharged and subsequently reviewed in the clinic. Based on the most recent imaging and evidence of disease progression, a new treatment regimen of exemestane combined with everolimus was initiated.

Indexed as

capecitabinecapecitabine-induced diarrhoeacapecitabine side effectsfluoropyrimidineileitisterminal ileitis

Identifiers

PMID41054681
PMCPMC12497393

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.